US clears MedicalCV's latest cardiac ablation system:
This article was originally published in Clinica
Executive Summary
MedicalCV has received US FDA 510(k) clearance to market its second-generation laser system for ablating cardiac tissue during surgery. The AtriLaze malleable ablation probe, which can be used to treat atrial fibrillation in an open-heart surgical procedure, provides surgeons with flexibility in delivering laser energy in confined spaces, according to the Inver Grove Heights, Minnesota firm. The company said it also intended to develop a stand-alone, minimally invasive - ie closed-chest, beating heart - surgical procedure for ablating cardiac tissue as a potential means of treating AF.